Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1630913 | 1.00 | PTGIR (0.31) | PTGIRPTGER2 | |
| SCHEMBL11981968 | 0.76 | PTGER2 (0.37) | PTGIRPTGER2 | |
| SCHEMBL12762099 | 0.75 | — | — | |
| SCHEMBL28528515 | 0.72 | PTGIR (0.30) | PTGIRPTGER2 | |
| SCHEMBL12134651 | 0.72 | PTGER2 (0.34) | PTGIRPTGER2 | |
| SCHEMBL12134518 | 0.71 | PTGER2 (0.34) | PTGIRPTGER2 | |
| SCHEMBL12133364 | 0.70 | PTGIR (0.31) | PTGIRPTGER2 | |
| SCHEMBL6554388 | 0.69 | — | — | |
| SCHEMBL1633837 | 0.69 | — | — | |
| SCHEMBL28783242 | 0.69 | TSHR (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7932420-B2 | Lowering intraocular pressure; glaucoma | ALLERGAN, INC. (US) | 2011-04-26 | — | — | US | disclosed |
| US-20080167331-A1 | Novel sulfonamides | BURK ROBERT M | 2008-07-10 | — | — | US | disclosed |
| US-7314890-B2 | Sulfonamides | ALLERGAN, INC. (US) | 2008-01-01 | — | — | US | disclosed |
| US-20070043090-A1 | Novel Sulfonamides | ALLERGAN, INC. | 2007-02-22 | — | — | US | disclosed |
| EP-1042283-B1 | OMEGA-CYCLOALKYL-PROSTAGLANDIN E2 DERIVATIVES | ONO PHARMACEUTICAL CO (JP) | 2004-02-25 | — | — | EP | disclosed |
| US-20030186939-A1 | Omega-cycloalkyl-prostaglandin E2 derivatives | TANI KOUSUKE (JP) | 2003-10-02 | — | — | US | disclosed |
| US-6576785-B1 | ω-cycloalkyl-prostaglandin E2 derivatives | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-06-10 | — | — | US | disclosed |
| EP-0860430-B1 | Omega-cycloalkyl-prostaglandin E2 derivatives | ONO PHARMACEUTICAL CO (JP) | 2002-06-12 | — | — | EP | disclosed |
| US-6262293-B1 | CLATHRATE COMPOUNDS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2001-07-17 | — | — | US | disclosed |
| EP-1042283-A1 | $g(v)-CYCLOALKYL-PROSTAGLANDIN E 2? DERIVATIVES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2000-10-11 | — | — | EP | disclosed |
| US-6110969-A | Cycloalkyl-prostaglandin E2 derivatives | ONO PHARMACEUTICAL CO. LTD. (JP) | 2000-08-29 | — | — | US | disclosed |
| WO-1999033794-A1 | φ-CYCLOALKYL-PROSTAGLANDIN E2 DERIVATIVES | ONO PHARMACEUTICAL CO., LTD. (JP) | 1999-07-08 | — | — | WO | disclosed |
| EP-0860430-A2 | Omega-cycloalkyl-prostaglandin E2 derivatives | ONO PHARMACEUTICAL CO., LTD. (JP) | 1998-08-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167331-A1 | Novel sulfonamides | NR2E3, NR5A2, HRH4 | PTGIR 226/4885PTGER2 962/4885 |
| US-20030186939-A1 | Omega-cycloalkyl-prostaglandin E2 derivatives | PTGER1, PTGER2, PTGER4 | PTGIR 7/4885PTGER2 2/4885 |
| US-20070043090-A1 | Novel Sulfonamides | NR2E3, NR5A2, HRH4 | PTGIR 226/4885PTGER2 962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.